Report period | 2017 | 2018 | 2019 | 2020 | 2021 | Q2 22 |
---|---|---|---|---|---|---|
End date of the reporting period | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Capitalization, ₽ | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Capitalization, $ | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Enterprise Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Book Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Shareholders Book Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Current liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Noncurrent liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Total liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Debt | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Cash and cash equivalents | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Net debt | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Assets | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Total ordinary shares | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Ordinary share price | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
ISKJ:RM | Human Stem Cells Institute | Common share | RUB 0.1 | RU000A0JNAB6 | RUB 94.12 |
Name | Issue size | Price | Yield |
---|---|---|---|
ISKJ BO-01 | 300,000 pcs. | 102.3% | 8.36% |
Company name | Human Stem Cells Institute |
---|---|
Tags | #biotechnology, #pharmacy, #innovations of the russia |
Sector | Health Care / Health Care Equipment & Services / Health Care Providers & Services / Health Care Services |
Business address | RF, g. Moskva |
Mailing address | 117036, g. Moskva, prospekt 60-letiya Oktyabrya, d. 10A, etazh 3, pom. 24 |
CEO | Masyuk Sergey Vladimirovich |
Phone | +7 (495) 646-80-76 |
Website | hsci.ru |
Information disclosure | e-disclosure.ru |